Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Event Review: My Cancer, My DNA - can genomics change the way we treat cancer?

21 March 2016

By Helen Robertson

Appeared in BioNews 844

My Cancer, My DNA: can genomics change the way we treat cancer?

Organised by Genetic Alliance UK

Thursday 10 March 2016 


'Personalised medicine' is a term that's being increasingly used to describe the future of cancer treatment. But what is really meant – and what do we understand – by the concept of making treatment unique to an individual?

Organised by Genetic Alliance UK as part of their 'Genome Seq Week', 'My Cancer, My DNA: can genomics change the way we treat cancer?' was an event that aimed to answer these questions and encourage discussion around the 100,000 Genomes Project and the use of genetic information in the NHS.

The evening began with a welcome by Alastair Kent, Director of Genetic Alliance UK, a charity that represents patients suffering from rare genetic conditions. He introduced the background to the 100,000 Genomes Project, an exciting initiative launched by Genomics England in 2012 to sequence 100,000 whole genomes by 2017. It will be sequencing the genomes of patients with rare genetic disorders as well as the genomes of cells taken from the tumours of common cancers.

Genetic testing is most commonly discussed with patients who are directly involved in genetic studies. As genetic testing becomes ever more widely used, it is increasingly important to engage the general public in similar discussions, said Kent. He emphasised that the majority of patients are overwhelmingly supportive of genetic sequencing and the sharing of data to aid research. The purpose of this event – of which more are planned in the future – was to see if the opinion of the general public matched those of patients.

Dr Katie Snape, lead consultant for cancer genetics at St George's Hospital in London, outlined how genomics will be used in healthcare – and specifically in cancer treatment – in the future.

In recent years, DNA sequencing has become far more accessible – it is now quicker and cheaper than ever to sequence a genome. Dr Snape used the clever analogy of the evolution of video games in the last few decades to illustrate her point. Early sequencing technologies of the 1990s gave us a Pac-Man perspective of the human genome, she said; modern technology means we're now playing the genetic equivalent of Grand Theft Auto. While the premise of the game has stayed broadly the same – driving a character around a track (or understanding how genetic changes might cause disease) – the resolution and amount of information available has increased exponentially.

But getting meaningful information from genetic data is an overwhelming task. With over 100 million differences between the genomes of two individuals, how can scientists identify which ones to target treatments towards?

There are already some treatments that are tailored to particular variants of cancer. Certain hereditary breast or ovarian cancers – where known predisposing mutations are inherited from one or both parents – are now treated with drugs targeted at those mutations. But the majority of cancers are 'sporadic' – that is, caused by random mutations acquired over the lifetime of the patient. The 100,000 Genomes Project aims to sequence the complete genomes of cells taken from the tumours of 25,000 cancer patients over varying stages of disease progression. By tracking mutations in the DNA of cancer cells, researchers hope to identify changes that could be specifically targeted to develop treatments on an individual basis.

Dr Clare Turnbull, clinical lead for inherited cancers at the 100,000 Genome Project, gave the second talk of the evening, on the technical logistics of implementing the project and its longer-term objectives. She explained that the aim is to put genomics at the centre of our healthcare system but said that, for now, this remains an ambitious hope for the future.

Following the talks, the audience was invited to give their opinions on three main aspects of the project – would we share our own genetic data to aid research; what did 'genome sequencing' mean to us; and if we had the opportunity to be tested for all potential genetic diseases, would we choose to have this knowledge? For the most part, the audience's answers were similar to those of patients involved in the 100,000 Genomes Project. Sharing genetic data was viewed favourably, and genome sequencing perceived as an exciting and beneficial technology, albeit one that that should be approached carefully.

The most conflicting perspectives within the audience were on how much knowledge individuals would want to have about their own predisposition to genetic conditions. Interestingly, this is something that mirrors the opinion of family members of patients.

For example, a surprising point that was raised is that young relatives of individuals with Huntington's disease often choose not to be tested. It seems that when the prospect of knowing your disease risk becomes a reality, people would rather not know. This is particularly pertinent for the possible applications of genome sequencing in the future. Sequencing genomes at birth, and releasing disease-risk information to individuals over their lifetime is still science fiction for now – but if that became a reality, how would it be received by society, and how would that information change the way we live our lives?

The event was interesting and informative, and certainly provided a broad background to the thinking behind the 100,000 Genomes Project and the prospect of individualised cancer treatment. I felt that the venue for the event and the relatively small audience would have lent itself to a more extended discussion and debate, particularly surrounding such issues as health insurance, data anonymity and data storage.

I left with a greater understanding of genome sequencing, but also with the feeling that many important questions surrounding the future of genetic data remained unanswered. As genomics becomes an increasingly important aspect of healthcare, keeping informed of how our data is being acquired and shared is important for all of us.

As for whether I'd want to know all the secrets of my own genome, I'm still on the fence. For now, perhaps, ignorance really is bliss.

SOURCES & REFERENCES

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

10 July 2017 - by Dr Rachel Brown 
A packed public event, produced by the Progress Educational Trust in partnership with Genomics England, saw the Chief Medical Officer for England launch her report 'Generation Genome'...
19 September 2016 - by Rhys Baker 
Personalised Medicine. A promise of medical treatment tailored to the individual. A promise that has been decades in the delivery. But now, as such treatment appears to be within reach, will the dream be dashed by bureaucracy, inertia and funding crises?...
20 June 2016 - by Rikita Patel 
Genomics could help predict drug side effects in patients with type 2 diabetes early in the drug development process, according to a study...
13 June 2016 - by Kulraj Singh Bhangra 
The US National Institutes of Health has announced a new initiative that encourages the sharing of genomic and clinical data among researchers across the world...
04 April 2016 - by Dr James Heather 
Hospitals around the UK are going to start examining the DNA of tumour cells from paediatric cancer patients in a pilot study starting later this year...

14 March 2016 - by Isobel Steer 
Genetic-testing company Ambry Genetics has launched a huge database of cancer-patient genetics, freely available to the public...
07 March 2016 - by Antony Blackburn-Starza 
Genome sequencing in Scotland has received a major cash boost, following a £6 million investment into the Scottish Genomes Partnership (SGP), which will begin working with Genomics England on the 100,000 Genomes Project...
15 February 2016 - by Kulraj Singh Bhangra 
US start-up company Sure Genomics has launched the first whole-genome testing service available directly to consumers, for a cost of $2500...
15 February 2016 - by Dr James Heather 
The prolific and popular 'Stuff You Should Know' podcast takes us down the pub to talk personalised medicine...
18 January 2016 - by Dr Molly Godfrey 
Two girls have become the first children to be diagnosed with rare genetic conditions through the 100,000 Genomes Project – the NHS DNA-sequencing initiative...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation